Point of View, Research Update 03.20.18 Share on Twitter Share on Facebook Share on LinkedIn Cell Therapy for Cancer: Past, Present and Future What does cell therapy in cancer look like today, and what will this exploding field look like in the future? This has been a milestone year for cell therapy, with FDA approval of the first adoptive CAR T-cell therapies for acute myeloid leukemia and some large B-cell lymphomas. But there is much more on the horizon. Watch Jeff Bluestone, PhD, president and CEO of the Parker Institute for Cancer Immunotherapy, and Crystal Mackall, MD, center director of the Parker Institute at Stanford Medicine, discuss new approaches, strategies and technologies for cell-based therapies that will continue to transform precision medicine. This talk was recorded at the Precision Medicine World Conference in January 2018 in Silicon Valley. Related Research Update CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse? Announcement PICI 2024: Collaborative Breakthroughs in Cancer Immunotherapy Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research
Research Update CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse?
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research